BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 26830088)

  • 1. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
    Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
    J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.
    Elson A; Paulson E; Bovi J; Siker M; Schultz C; Laviolette PS
    J Neurooncol; 2015 May; 123(1):179-88. PubMed ID: 25894597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Whole brain apparent diffusion coefficient measurements correlate with survival in glioblastoma patients.
    Rulseh AM; Vymazal J
    J Neurooncol; 2020 Jan; 146(1):157-162. PubMed ID: 31797235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
    Paik W; Kim HS; Choi CG; Kim SJ
    Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
    Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
    Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study.
    Pope WB; Qiao XJ; Kim HJ; Lai A; Nghiemphu P; Xue X; Ellingson BM; Schiff D; Aregawi D; Cha S; Puduvalli VK; Wu J; Yung WK; Young GS; Vredenburgh J; Barboriak D; Abrey LE; Mikkelsen T; Jain R; Paleologos NA; Lada P; Prados M; Goldin J; Wen PY; Cloughesy T
    J Neurooncol; 2012 Jul; 108(3):491-8. PubMed ID: 22426926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
    Suchorska B; Weller M; Tabatabai G; Senft C; Hau P; Sabel MC; Herrlinger U; Ketter R; Schlegel U; Marosi C; Reifenberger G; Wick W; Tonn JC; Wirsching HG
    Neuro Oncol; 2016 Apr; 18(4):549-56. PubMed ID: 26823503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.
    Ellingson BM; Sahebjam S; Kim HJ; Pope WB; Harris RJ; Woodworth DC; Lai A; Nghiemphu PL; Mason WP; Cloughesy TF
    AJNR Am J Neuroradiol; 2014 Apr; 35(4):673-9. PubMed ID: 24136647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.
    Rahman R; Hamdan A; Zweifler R; Jiang H; Norden AD; Reardon DA; Mukundan S; Wen PY; Huang RY
    J Neurooncol; 2014 Aug; 119(1):149-58. PubMed ID: 24805151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
    Wen Q; Jalilian L; Lupo JM; Molinaro AM; Chang SM; Clarke J; Prados M; Nelson SJ
    J Neurooncol; 2015 Jan; 121(2):331-9. PubMed ID: 25351579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.
    Zhang M; Gulotta B; Thomas A; Kaley T; Karimi S; Gavrilovic I; Woo KM; Zhang Z; Arevalo-Perez J; Holodny AI; Rosenblum M; Young RJ
    Neuro Oncol; 2016 May; 18(5):735-43. PubMed ID: 26538618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
    Ellingson BM; Cloughesy TF; Lai A; Mischel PS; Nghiemphu PL; Lalezari S; Schmainda KM; Pope WB
    Neuro Oncol; 2011 Oct; 13(10):1151-61. PubMed ID: 21856685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery.
    Roder C; Bisdas S; Ebner FH; Honegger J; Naegele T; Ernemann U; Tatagiba M
    Eur J Surg Oncol; 2014 Mar; 40(3):297-304. PubMed ID: 24411704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of absolute and normalized apparent diffusion coefficient (ADC) values within the post-operative T2/FLAIR volume as adverse prognostic indicators in glioblastoma.
    Elson A; Bovi J; Siker M; Schultz C; Paulson E
    J Neurooncol; 2015 May; 122(3):549-58. PubMed ID: 25700835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.
    Patel KS; Everson RG; Yao J; Raymond C; Goldman J; Schlossman J; Tsung J; Tan C; Pope WB; Ji MS; Nguyen NT; Lai A; Nghiemphu PL; Liau LM; Cloughesy TF; Ellingson BM
    Neurosurgery; 2020 Oct; 87(5):931-938. PubMed ID: 32365185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
    Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
    PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
    Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
    Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histogram analysis of apparent diffusion coefficient maps in the prognosis of patients with locally advanced head and neck squamous cell carcinoma: Comparison of different region of interest selection methods.
    Ren JL; Yuan Y; Li XX; Shi YQ; Tao XF
    Eur J Radiol; 2018 Sep; 106():7-13. PubMed ID: 30150054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can MRI-derived factors predict the survival in glioblastoma patients treated with postoperative chemoradiation therapy?
    Nakamura H; Murakami R; Hirai T; Kitajima M; Yamashita Y
    Acta Radiol; 2013 Mar; 54(2):214-20. PubMed ID: 23138021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.